hasPipeline
P129093
predicate
Indicates that one entity possesses, contains, or is associated with a pipeline used to transport or process something.
All labels observed (2)
| Label | Occurrences |
|---|---|
| hasPipeline canonical | 18 |
| hasPipelineNetwork | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasPipeline
Generated description
Indicates that one entity possesses, contains, or is associated with a pipeline used to transport or process something.
Sample triples (19)
| Subject | Object |
|---|---|
|
ALNY
surface form:
Alnylam Pharmaceuticals, Inc.
|
RNAi therapeutics in clinical development ⓘ |
| Vir Biotechnology | monoclonal antibody candidates ⓘ |
| Vir Biotechnology | T cell–based candidates ⓘ |
| Vir Biotechnology | vaccinal approaches ⓘ |
| Array BioPharma | early-stage oncology programs ⓘ |
| Array BioPharma | late-stage oncology programs ⓘ |
| Akcea Therapeutics | RNA-targeted drugs for lipid disorders ⓘ |
| Akcea Therapeutics | RNA-targeted drugs for amyloidosis ⓘ |
| Akcea Therapeutics | RNA-targeted drugs for cardiometabolic risk reduction ⓘ |
|
ALKS
surface form:
Alkermes plc
|
CNS drug candidates ⓘ |
|
ALKS
surface form:
Alkermes plc
|
oncology drug candidates ⓘ |
| Exicure | preclinical SNA-based therapeutics ⓘ |
| Exicure | clinical-stage SNA-based therapeutics ⓘ |
| Editas Medicine | inherited retinal disease programs ⓘ |
| Editas Medicine | sickle cell disease programs ⓘ |
| Editas Medicine | beta-thalassemia programs ⓘ |
| Oil India Limited | crude oil pipelines in Northeast India via predicate surface "hasPipelineNetwork" ⓘ |
| Synergistic Processing Element | dual-issue pipeline ⓘ |
| NantKwest | clinical-stage NK cell therapeutics ⓘ |